Historical Valuation
Arrowhead Pharmaceuticals Inc (ARWR) is now in the Fair zone, suggesting that its current forward PS ratio of 22.22 is considered Fairly compared with the five-year average of -25.65. The fair price of Arrowhead Pharmaceuticals Inc (ARWR) is between 31.28 to 94.43 according to relative valuation methord.
Relative Value
Fair Zone
31.28-94.43
Current Price：65.88
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Arrowhead Pharmaceuticals Inc (ARWR) has a current Price-to-Book (P/B) ratio of 19.74. Compared to its 3-year average P/B ratio of 12.11 , the current P/B ratio is approximately 62.98% higher. Relative to its 5-year average P/B ratio of 12.70, the current P/B ratio is about 55.45% higher. Arrowhead Pharmaceuticals Inc (ARWR) has a Forward Free Cash Flow (FCF) yield of approximately 1.70%. Compared to its 3-year average FCF yield of -11.71%, the current FCF yield is approximately -114.54% lower. Relative to its 5-year average FCF yield of -7.13% , the current FCF yield is about -123.89% lower.
P/B
Median3y
12.11
Median5y
12.70
FCF Yield
Median3y
-11.71
Median5y
-7.13
Competitors Valuation Multiple
AI Analysis for ARWR
The average P/S ratio for ARWR competitors is 8.97, providing a benchmark for relative valuation. Arrowhead Pharmaceuticals Inc Corp (ARWR.O) exhibits a P/S ratio of 22.22, which is 147.8% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ARWR
1Y
3Y
5Y
Market capitalization of ARWR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ARWR in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ARWR currently overvalued or undervalued?
Arrowhead Pharmaceuticals Inc (ARWR) is now in the Fair zone, suggesting that its current forward PS ratio of 22.22 is considered Fairly compared with the five-year average of -25.65. The fair price of Arrowhead Pharmaceuticals Inc (ARWR) is between 31.28 to 94.43 according to relative valuation methord.
What is Arrowhead Pharmaceuticals Inc (ARWR) fair value?
ARWR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Arrowhead Pharmaceuticals Inc (ARWR) is between 31.28 to 94.43 according to relative valuation methord.
How does ARWR's valuation metrics compare to the industry average?
The average P/S ratio for ARWR's competitors is 8.97, providing a benchmark for relative valuation. Arrowhead Pharmaceuticals Inc Corp (ARWR) exhibits a P/S ratio of 22.22, which is 147.80% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Arrowhead Pharmaceuticals Inc (ARWR) as of Jan 09 2026?
As of Jan 09 2026, Arrowhead Pharmaceuticals Inc (ARWR) has a P/B ratio of 19.74. This indicates that the market values ARWR at 19.74 times its book value.
What is the current FCF Yield for Arrowhead Pharmaceuticals Inc (ARWR) as of Jan 09 2026?
As of Jan 09 2026, Arrowhead Pharmaceuticals Inc (ARWR) has a FCF Yield of 1.70%. This means that for every dollar of Arrowhead Pharmaceuticals Inc’s market capitalization, the company generates 1.70 cents in free cash flow.
What is the current Forward P/E ratio for Arrowhead Pharmaceuticals Inc (ARWR) as of Jan 09 2026?
As of Jan 09 2026, Arrowhead Pharmaceuticals Inc (ARWR) has a Forward P/E ratio of -21.43. This means the market is willing to pay $-21.43 for every dollar of Arrowhead Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Arrowhead Pharmaceuticals Inc (ARWR) as of Jan 09 2026?
As of Jan 09 2026, Arrowhead Pharmaceuticals Inc (ARWR) has a Forward P/S ratio of 22.22. This means the market is valuing ARWR at $22.22 for every dollar of expected revenue over the next 12 months.